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1. INTRODUCTION {#jcp29104-sec-0010}
===============

Gliomas are the most frequently diagnosed intracranial malignancies with high morbidity and mortality in worldwide (de Robles et al., [2015](#jcp29104-bib-0005){ref-type="ref"}). They are characterized by rapid metastasis and aggressive infiltration, leading to poor prognosis (Diksin, Smith, & Rahman, [2017](#jcp29104-bib-0006){ref-type="ref"}; Ostrom et al., [2014](#jcp29104-bib-0020){ref-type="ref"}). According to World Health Organization Classification of Tumors of the Central Nervous System proposed in 2016, glioblastoma (GBM) is the most common type of malignant gliomas, and the mean survival time of GBM patients is only approximately 15 months, even after systematic treatments (Lara‐Velazquez et al., [2017](#jcp29104-bib-0010){ref-type="ref"}; Louis et al., [2016](#jcp29104-bib-0015){ref-type="ref"}). Growing evidence have demonstrated that the malignant degree of gliomas may be attributed to various genetic and epigenetic alterations in tumorigenesis (Masui, Kato, Sawada, Mischel, & Shibata, [2017](#jcp29104-bib-0018){ref-type="ref"}; Tsankova & Canoll, [2014](#jcp29104-bib-0023){ref-type="ref"}). Exploring the molecular mechanisms underlying the aggressive progression of glioma may provide the novel therapeutic targets for the fatal cancer.

Poly(C) binding protein 2 (PCBP2), a RNA‐binding protein with 39 kDa, can regulate RNA stabilization, translational silencing and enhancement (Collier, Goobar‐Larsson, Sokolowski, & Schwartz, [1998](#jcp29104-bib-0004){ref-type="ref"}; Wan et al., [2016](#jcp29104-bib-0025){ref-type="ref"}). It contains three K homology domains employed as the main RNA recognized regions (Chen et al., [2016](#jcp29104-bib-0003){ref-type="ref"}; Leffers, Dejgaard, & Celis, [1995](#jcp29104-bib-0011){ref-type="ref"}). Dysregulation of *PCBP2* may damage multiple biological processes through RNA‐binding pathways. For instance, *PCBP2* could regulate the genome circularization and replication of various RNA viruses, like norovirus (Lopez‐Manriquez et al., [2013](#jcp29104-bib-0014){ref-type="ref"}), severe acute respiratory syndrome coronaviruses (SARS‐CoV; Shi et al., [2014](#jcp29104-bib-0021){ref-type="ref"}), poliovirus (Walter, Parsley, Ehrenfeld, & Semler, [2002](#jcp29104-bib-0024){ref-type="ref"}), and hepatitis C virus (Li, Masaki, Shimakami, & Lemon, [2014](#jcp29104-bib-0012){ref-type="ref"}). The upregulation of *PCBP2* may contribute to the formation of ribosomal initiation complex, thus enhancing the replication of virus (Asnani, Pestova, & Hellen, [2016](#jcp29104-bib-0001){ref-type="ref"}). Additionally, *PCBP2* could regulate cell growth, migration and invasion (Chen et al., [2018](#jcp29104-bib-0002){ref-type="ref"}; Mao et al., [2016](#jcp29104-bib-0017){ref-type="ref"}). The abnormalities in *PCBP2* expression have been observed in several cancers, such as gastric cancer (Chen et al., [2018](#jcp29104-bib-0002){ref-type="ref"}) and hepatocellular carcinoma (Zhang et al., [2016](#jcp29104-bib-0027){ref-type="ref"}). In glioma, it has been reported that the knockdown of PCBP may inhibit tumor cell proliferation and growth (Tang, Gao, & Chen, [2015](#jcp29104-bib-0022){ref-type="ref"}). *PCBP2* may act as an oncogene in etiology of glioma. However, the molecular mechanisms of *PCBP2* in glioma progression was poorly known.

In this study, we investigated the expression of *PCBP2* in glioma tissues and cells and revealing its functional roles in glioma progression. Furthermore, cell experiments were constructed to explore the molecular mechanisms underlying the oncogenic function of *PCBP2* in the pathogenesis of glioma.

2. MATERIALS AND METHODS {#jcp29104-sec-0020}
========================

2.1. Patients and tissue samples collection {#jcp29104-sec-0030}
-------------------------------------------

The present study was carried out in Harrison international Peace Hospital. A total of 106 adult glioma patients who were diagnosed through pathological examinations were enrolled in our study. Glioma tissues and corresponding noncancerous tissues were collected from the patients who received surgical procedures and put into liquid nitrogen immediately. Then the specimens were stored at −80℃ for usage in the next step. None of the patients had received any treatments before tissue collection, such as chemotherapy or/and radiotherapy. Clinical characteristics of glioma patients were also obtained from medical records. This study was approved by the Ethics Committee of Harrison international Peace Hospital. All patients had signed the written informed contents.

2.2. Cell culture {#jcp29104-sec-0040}
-----------------

Human glioma cell line U251 and normal glial cell HEB were purchased from Cell Bank of Shanghai Institutes for Biological Science (Shanghai, China). Cells were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM; Life Technologies) supplemented with 10% fetal bovine serum (FBS; Life Technologies). The cells were incubated at 37℃ with 5% CO~2~. Medium for cell culture was changed every 2--3 days.

2.3. Quantitative real‐time polymerase chain reaction (qRT‐PCR) {#jcp29104-sec-0050}
---------------------------------------------------------------

Total RNA of glioma tissues and cell specimens was extracted employing TRizol reagent (Invitrogen, Carlsbad, CA) following the instruction of the manufacturer. Quality and concentration of RNA samples were checked using NanoDrop 1000 spectrophotometer (Thermo Scientific, Wilmington, DE). Complementary DNA (cDNA) was synthesized via reverse‐transcription reaction which was completed using PrimerScript RT reagent kit (Takara, Chiga, Japan). Relative expression of *PCBP2* mRNA was estimated using qRT‐PCR. qRT‐PCR reactions were performed by SYBR Green PCR Master Mix (Applied Biosystems) in the 7900 Real‐time PCR System (Applied Biosystems). Specific primer sequences for genes were as follows: *PCBP2* forward: 5′‐AGGCAGGTTACCATCACTGG‐3′, reverse: 5′‐CATTGTTCTAGCTGCTCCCC‐3′; *FHL3* forward: 5′‐CATGGCATGAGCACTGCTTCCTG‐3′, reverse: 5′‐GCTTAGGGCCCTGCCTGGCTACAGC‐3′. *GAPDH* was employed as the internal control, and its primer sequences were as the following, forward: 5′‐TGCACCACCAACTGCTTAGC‐3′; reverse: 5′‐GGCATGGACTGTGGTCATGAG‐3′. The relative expression level of the detected genes was calculated using $2^{- \Delta\Delta C_{t}}$ method. Each test was repeated three times.

2.4. Immunohistochemistry (IHC) {#jcp29104-sec-0060}
-------------------------------

Protein expression of PCBP2 in glioma tissue samples were estimated using IHC analysis staining with streptavidin‐perosidase (S‐P). IHC kit (Boster, Wuhan, China) was used according to manufacturer\'s instruction. The used antibody included anti‐*PCBP2* antibody (1:200, Abcam, UK). Staining results were recorded by two independent investigators, and they did not know the histopathologic features and patients' information. Staining results were scored according to the following standards: 0: for staining \< 5%; 1: staining 6--25%; 2: staining 26--50%; 3: staining 51--75%; 4: staining \> 75%. Patients with score \<1 were confirmed as negative staining, otherwise, the patients were confirmed as positive staining.

2.5. Vector construction and cell transfection {#jcp29104-sec-0070}
----------------------------------------------

To investigate the role of *PCBP2* in glioma progression, siRNA‐*PCBP2* was designed to silence *PCBP2* expression in glioma cells in vitro. si‐*PCBP2* and corresponding negative control (si‐NC) sequences were synthesized by GenePharma (Shanghai, China). The obtained sequences were cloned into pLV‐shRNA plasmid, and then transfected into giloma cells using Lipofectamine^TM^ 2000 (Invitrogen, Thermo Fisher Scientific, Inc.). Transfection for 48 hr, qRT‐PCR was conducted to measure the relative expression of *PCBP2* so as to estimate the transfection effects.

In addition, to explore the molecular mechanisms underlying the function of *PCBP2* in the progression of glioma, si‐*FHL3* and *FHL3*‐overexpression (pLV‐*FHL3*) recombinant plasmids and corresponding controls were also constructed.

2.6. 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assay {#jcp29104-sec-0080}
-----------------------------------------------------------------------------

The effect of *PCBP2* on the proliferation of glioma cells were tested via MTT assay. After the cultivation of 48 hr, the transfected cells were seeded to 96‐well plate (5 × 10^3^ cells/well). The cells were incubated at the specific condition (37℃, 5% CO~2~). Each well was added 20 µl MTT (5 mg/ml; Sigma, St. Louis, MO) when transfected cells were incubated for 0, 24, 48, and 72 hr, respectively, and an additional 4 hr was needed to maintain the incubation. Then, 150 µl dimethyl sulfoxide (DMSO, Sigma‐Aldrich) was added to dissolve the purple formazan for 15 min. And then the absorbance at 490 nm was read by a Microplate Reader (TECAN, Salzburg, Austria).

2.7. Transwell assay {#jcp29104-sec-0090}
--------------------

Cell migration and invasion abilities were tested using Transwell chambers coated or not by Matrigel (Corning Glass Works, Corning, NY) on the upper chamber, respectively. The upper chamber of Transwell (Corning Glass Works, Corning, NY) was added 200 µl serum‐free medium, the bottom chamber was filled with the medium containing 10% FBS. Transfected cells with the density of 4 × 10^4^/ml were seeded to the upper chamber. Incubation for 48 hr, the number of cells at the bottom chamber were determined by crystal violet staining and quantified using a inverted microscope (Leica, Malvern, PA) in 10 random fields.

2.8. Flow cytometry {#jcp29104-sec-0100}
-------------------

Flow cytometry with Annexin V/PI double staining method was applied to detect cell apoptosis rate. After transfection for 48 hr, the cells were collected and adjusted to the density of 1 × 10^6^/ml. Then they were stained by Annexin V FITC/PI (fluorescein isothiocyanate/propidium iodide) Apoptosis Detection Kit (Beyotime) according to the manufacturer\'s specification. Apoptosis rate was assessed by flow cytometry (BD Biosciences, San Jose, CA). Each test was repeated in triplicate.

2.9. Luciferase reporter assay {#jcp29104-sec-0110}
------------------------------

3′‐Untranslated region (3′‐UTR) of *FHL3* gene contained the putative binding site of *PCBP2*. PCR method was used to amplify 3′‐UTR of *FHL3*, and then it was cloned to p‐GL3 vector (Promega, Madison, WI) containing firefly luciferase reporter gene (wild‐type \[WT\]). In addition, 3′UTR of *FHL3* with a mutant sequence of *PCBP2* binding site was also amplified and cloned to the vector (mutate type \[MT\]). Then the vectors were transfected into U251 cells with or without si‐*PCBP2* vector. Transfection for 48 hr, the cells were harvested and the luciferase activity was detected using a dual‐luciferase reporter assay system (Promega) and normalized to Renilla activity.

2.10. Western blot analysis {#jcp29104-sec-0120}
---------------------------

Expression of proteins was detected using western blot analysis. Precold radioimmunoprecipitation assay buffer (RIPA buffer) (Beyotime, Shanghai, China) with protease inhibitor was used to isolate protein samples from the cells and protein samples were extracted and quantified by a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, San Jose, CA). The equal protein was separated in 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis, and transferred to the polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA) at 48 V for 3.5 hr. Then 5% bovine serum albumin (BSA) was applied to incubate the membranes at room temperature for 2 hr. After washing by 1 × Tris‐buffer saline with Tween 20 (TBST), the membranes were blocked for 60 min and incubated for 1 hr at room temperature after adding the primary antibodies: mouse anti‐human TGF‐β1 (1:1,000), p‐Smad2 (1:1,000), p‐Smad7 (1:1,000), and Smad2 (1:1,000), and Smad7 (1:1,000) (Cell Signaling Technologies, Beverly, MA). Next, the membranes were incubated with the secondary goat anti‐rabbit antibody (1:4,000; Cell Signaling Technologies, Beverly, MA), and visualized under UV transilluminator (Uvitec Ltd., Avebury House, Cambridge, UK). β‐Actin was acted as an internal control. Protein levels were quantified based on gray value. Each test was repeated three times.

2.11. Animal assay {#jcp29104-sec-0130}
------------------

Twenty Balb/c nude mice (6--8 weeks) were routinely cultured, U251 cells (3 × 10^6^/200 μl) were inoculated on the upper part of the groin, mice were performed the subcutaneous injection. They were equally divided into two groups: experimental group (si‐*PCBP2*) and the control group (si‐NC), every group was 10 cases. The major axis (a) and minor axis (b) of the subcutaneous tumor were measured once 3 days, tumor volume: V = 1/2 × a × b^2^. After 4 weeks, nude mice were killed for the measurement of tumor weight.

2.12. Statistical analysis {#jcp29104-sec-0140}
--------------------------

All the data analysis and figure drawing were performed using SPSS 18.0 software (SPSS Inc., Chicago, IL), and GraphPad Prism version 5.0 (GraphPad, San Diego, CA), respectively. Continuous variables were shown as mean ± standard deviation (*SD*). Comparison between case and control groups via student\'s *t* test. *χ* ^2^ test was used to explore the association of *PCBP2* expression with clinical parameters of glioma patients. *p \< *.05 were considered as statistical significance.

3. RESULTS {#jcp29104-sec-0150}
==========

3.1. Characteristics of study subjects {#jcp29104-sec-0160}
--------------------------------------

A total of 106 glioma patients were enrolled in our study, including 55 males and 51 females. The average age of glioma patients was 54.28 ± 11.025 years. Forty‐four patients had family history of cancer, and the tumor size of 49 patients were larger than 5 cm. According to World Health Organization (WHO) classification, 65 patients were confirmed as Stage I‐II, and 41 patients were Stage III‐IV. The clinical characteristics of the patients were summarized in Table [1](#jcp29104-tbl-0001){ref-type="table"}.

###### 

The influences of *PCBP2* expression on clinical characteristics of glioma patients

  Characteristics   N (*n* = 106)   *PCBP2* low expression (*n* = 58)   *PCBP2* high expression (*n* = 48)   *p* values
  ----------------- --------------- ----------------------------------- ------------------------------------ ------------
  Age (years)                                                                                                .072
  ≥60               43              19                                  24                                   
  \<60              63              39                                  24                                   
  Gender                                                                                                     .669
  Male              55              29                                  26                                   
  Female            51              29                                  22                                   
  Family history                                                                                             .107
  Yes               44              20                                  24                                   
  No                62              38                                  24                                   
  Tumor size (cm)                                                                                            .001
  \<5               57              40                                  17                                   
  ≥5                49              18                                  31                                   
  KPS scores                                                                                                 .588
  ≥70               39              20                                  19                                   
  \<70              67              38                                  29                                   
  WHO stage                                                                                                  .010
  I‐II              65              42                                  23                                   
  III‐IV            41              16                                  25                                   

Abbreviations: KPS, Karnofsky performance score; PCBP2, poly (C)‐binding protein 2; WHO, World health organization.
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3.2. Expression patterns of PCBP2 in glioma tissues and cells {#jcp29104-sec-0170}
-------------------------------------------------------------

mRNA levels of *PCBP2* were detected using qRT‐PCR in glioma tissues and cells. Analysis results demonstrated that *PCBP2* mRNA level was significantly higher in glioma tissues and cells than that in noncancerous tissues and normal cells (*p* \< .01 for both; Figure [1](#jcp29104-fig-0001){ref-type="fig"}a,b).Then the protein levels of *PCBP2* in glioma tissues were also examined by western blot assay. The data showed that *PCBP2* protein level in glioma tissues was significantly increased compared with noncancerous tissues (*p* \< 0.01; Figure [1](#jcp29104-fig-0001){ref-type="fig"}b). Additionally, IHC was applied to investigate the expression of *PCBP2* protein in glioma tissues. As shown in Figure [1](#jcp29104-fig-0001){ref-type="fig"}d, *PCBP2* exhibited the strong positive expression in glioma tissues, but weak positive expression in noncancerous tissues. The positive rate was 87.73% (93/106) in glioma tissues, while the positive rate was only 16.98% (18/106) in adjacent normal tissues. Expression of PCBP2 protein was obviously higher in glioma tissues than that in adjacent normal tissues.

![Poly (C)‐binding protein 2 (*PCBP2*) was upregulated in glioma tissues. The relative expression of PCBP2 mRNA in glioma tissue specimens and noncancerous tissues were examined by quantitative real‐time polymerase chain reaction (qRT‐PCR) assay (a). The levels of *PCBP2* in HEB cells and U251 cells were examined by qRT‐PCR assay (b). *PCBP2* protein expression in noncancerous tissues and glioma tissues were examined by western blot analysis (c). The representative immunohistochemical (IHC) staining images showing the expression patterns of *PCBP2* protein in noncancerous tissues and glioma tissues (×200) (d). Data are presented as mean ± *SD* (*n*  =  3). \*\**p*  \<  .01. *SD*, standard deviation](JCP-235-3280-g001){#jcp29104-fig-0001}

3.3. Association of PCBP2 mRNA levels with clinical characteristics of glioma patients {#jcp29104-sec-0180}
--------------------------------------------------------------------------------------

In this study, the relationship between *PCBP2* expression and clinical parameters of glioma patients was evaluated. The included patients were divided into high expression group (*n* = 48) and low expression group (*n* = 58) according to the mean level of *PCBP2* mRNA in glioma tissues. The results indicated that the high expression of *PCBP2* was positively associated with tumor size (*p* = .001), and advanced WHO stage (*p* = .010). However, the expression of *PCBP2* was not correlated with age, gender, family history, and KPS score of glioma patients (*p* \> .05 for all; Table [1](#jcp29104-tbl-0001){ref-type="table"}).

3.4. Effects of PCBP2 expression on biological behaviors of glioma cells in vitro {#jcp29104-sec-0190}
---------------------------------------------------------------------------------

To investigate the role of *PCBP2* in etiology of glioma, si‐*PCBP2* vector was constructed in our study. After transfection, qRT‐PCR and western blot analysis were used to detect the transfection efficiency of si‐PCBP2, the result indicated that the expression of *PCBP2* was remarkably downregulated in glioma cells which were transfected by si‐PCBP2 (*p* \< .001; Figure [2](#jcp29104-fig-0002){ref-type="fig"}a,b).

![The efficiency of si‐*PCBP2* was confirmed by quantitative real‐time polymerase chain reaction (a) and Western blot analysis (b). Data are presented as mean ± SD (*n* = 3). \*\*\**p* \< .001](JCP-235-3280-g002){#jcp29104-fig-0002}

Effects of *PCBP2* on biological behaviors of glioma cells were estimated in our study. MTT assay demonstrated that the knockdown of *PCBP2* could distinctly suppress the proliferation of glioma cells (*p* \< .05 and Figure [3](#jcp29104-fig-0003){ref-type="fig"}a). Migration and invasion abilities of glioma cells were also significantly inhibited after si‐*PCBP2* transfection, compare with si‐NC group (*p* \< .05, Figure [3](#jcp29104-fig-0003){ref-type="fig"}b,c). Furthermore, the apoptotic rate of si‐*PCBP2* transfected cells was obviously increased, compared with si‐NC group (*p* \< .001 and Figure [3](#jcp29104-fig-0003){ref-type="fig"}d). Therefore, the knockdown of *PCBP2* could obviously inhibit the progression of glioma cells.

![Effects of poly (C)‐binding protein 2 (*PCBP2*) expression on biological behaviors of glioma cells in vitro. The knockdown of *PCBP2* expression could significantly inhibit proliferation (a), migration (b) and invasion (c) of glioma cells. Furthermore, inhibition of *PCBP2* expression could promote cell apoptosis (d). Data are presented as mean ± *SD* (*n* = 3). \**p* \< .05, \*\**p* \< .01, and \*\*\**p* \< .001. *SD*, standard deviation](JCP-235-3280-g003){#jcp29104-fig-0003}

3.5. PCBP2 knockdown could promote FHL3 expression and suppress TGF‐β/Smad signaling pathway {#jcp29104-sec-0200}
--------------------------------------------------------------------------------------------

In our study, qRT‐PCR and western blot were carried out to investigate the expression of *FHL3* in si‐*PCBP2* transfected cells. The results suggested that the expression of *FHL3* was obviously increased in glioma cells with the knockdown of *PCBP2* (*p* \< .05 and Figure [4](#jcp29104-fig-0004){ref-type="fig"}a,b). *PCBP2* could regulate the expression of *FHL3* in glioma.

![Poly (C)‐binding protein 2 (*PCBP2*) knockdown could promote FHL3 expression and suppress TGF‐β/Smad signaling pathway. The knockdown of *PCBP2* could significantly enhance the expression of *FHL3* in glioma cells (a and b). Knockdown of *PCBP2* might inhibit the activity of TGF‐β/Smad signaling pathway (c). Data are presented as mean ± *SD* (*n* = 3). \**p* \< .05, \*\**p* \< .01, \*\*\**p* \< .001. *SD*, standard deviation](JCP-235-3280-g004){#jcp29104-fig-0004}

Moreover, western blot method was used to investigate the expressions of TGF‐β/Smad signaling pathway proteins in glioma cells transfected by si‐*PCBP2* and the results showed that the expression of TGF‐β1, p‐Smad2, and p‐Smad7 proteins were downregulated in glioma cells after *PCBP2* knockdown. However, the expression of Smad2 and Smad7 did not show obvious changes (Figure [4](#jcp29104-fig-0004){ref-type="fig"}c).

3.6. FHL3 was a potential target of PCBP2 in glioma {#jcp29104-sec-0210}
---------------------------------------------------

Luciferase reporter assay was used to investigate the link between *PCBP2* and *FHL3*. The glioma cell U251 was cotransfected by wt or mt and si‐*PCBP2* or si‐NC plasmids. The relative luciferase activity was significantly reduced after *PCBP2* knockdown in cells transfected by *FHL3*‐wt (*p* \< .01, Figure [5](#jcp29104-fig-0005){ref-type="fig"}a). However, the luciferase activity in cells transfected by *FHL3*‐mt did not show obvious changes after *PCBP2* silencing (NS: nonsignificant). All the data revealed the target relationship between *PCBP2* and *FHL3*.

![FHL3 was a potential target of poly (C)‐binding protein 2 (PCBP2) in glioma.The nucleotide sequence of FHL3 target binding site and the core recognition sequence are red (a). The loss of *PCBP2* expression could reduce the luciferase activity of cell transfected by *FHL3*‐wt, but it did not influence the cells transfected by *FHL3*‐mt (b). The transfection of pLV‐*FHL3* vector could distinctly enhance the expression of *FHL3* (c and d), but had no significant influence on *PCBP2* expression (e and f). Data are presented as mean ± *SD* (*n*  =  3). \*\**p*  \<  .01, (NS, nonsignificant, *p*  \>  .05)](JCP-235-3280-g005){#jcp29104-fig-0005}

Nucleotide sequence of FHL3 target binding site and the core recognition sequence are red (Figure [5](#jcp29104-fig-0005){ref-type="fig"}a and Han et al., [2013](#jcp29104-bib-0009){ref-type="ref"}). pLV‐*FHL3* vector was designed to enhance the expression of *FHL3* in glioma cells. The glioma cell line U251 was transfected by pLV‐*FHL3* and corresponding control (pLV‐NC) in vitro. qRT‐PCR method was used to investigate the relative expression of *PCBP2* and *FHL3* in transfected cells. Expression of *FHL3* mRNA was significantly increased after pLV‐*FHL3* transfection (*p* \< .01, Figure [5](#jcp29104-fig-0005){ref-type="fig"}b), while *PCBP2* expression did not show obvious changes (*p* \> .05, Figure [5](#jcp29104-fig-0005){ref-type="fig"}d). The results of western blot analysis was also showed after pLV‐*FHL3* transfection, the expression of *FHL3* protein was increased significantly (*p* \< 0.01 and Figure [5](#jcp29104-fig-0005){ref-type="fig"}c), while the expression of *PCBP2* did not change significantly (*p* \> .05 and Figure [5](#jcp29104-fig-0005){ref-type="fig"}e). Therefore, *PCBP2* could inhibit *FHL3* expression, while *FHL3* did not influence *PCBP2* expression. The data indicated that *FHL3* was located on the downstream of *PCBP2*. *FHL3* might be a potential target gene of *PCBP2* in glioma.

3.7. Oncogenic function of PCBP2 in glioma was mediated by FHL3 {#jcp29104-sec-0220}
---------------------------------------------------------------

To explore the molecular mechanisms of *PCBP2* in the progression of glioma, U251 was cotransfected by si‐*PCBP2* and si‐*FHL3*. Western blot analysis suggested that compared with glioma cells only transfected by si‐*PCBP2*, the cotransfection of si‐*PCBP2* and si‐*FHL3* could significantly enhance the expression of TGF‐β1, p‐Smad2, and p‐Smad7 proteins, suggesting the activation of TGF‐β/Smad signaling pathway (Figure [6](#jcp29104-fig-0006){ref-type="fig"}).

![The knockdown of *FHL3* expression could enhance the expression patterns of TGF‐β/Smad signaling pathway proteins in glioma cells transfected by si‐*PCBP2* vector. \**p* \< .05, \*\**p* \< .01](JCP-235-3280-g006){#jcp29104-fig-0006}

In addition, the proliferation (*p* \< .05, Figure [7](#jcp29104-fig-0007){ref-type="fig"}a), migration (*p* \< .01 and Figure [7](#jcp29104-fig-0007){ref-type="fig"}b) and invasion (*p* \< .01 and Figure [7](#jcp29104-fig-0007){ref-type="fig"}c) abilities of cotransfected cells were distinctly enhanced, and the cell apoptosis (*p* \< .001 Figure [7](#jcp29104-fig-0007){ref-type="fig"}d) was decreased. All the data revealed that si‐*FHL3* transfection could reverse the antitumor action caused by the knockdown of *PCBP2* in glioma.

![Inhibition of *FHL3* expression could reverse the antitumor actions induced by the knockdown of poly (C)‐binding protein 2 (*PCBP2*) in glioma cells in vitro. Compared to the control groups, the cells proliferation (a), migration (b) and invasion (c) were significantly enhanced, while cell apoptosis (d) was downregulated in + si‐*FHL3* group. The cells in control group were transfected by si‐*PCBP2* vector only, while the cells in + si‐*FHL3* group were cotransfected by si‐*PCBP2* and si‐*FHL3* vectors. Data are presented as mean ± *SD* (*n* = 3). \**p* \< .05, \*\**p* \< .01, and \*\*\**p* \< .001. *SD*, standard deviation](JCP-235-3280-g007){#jcp29104-fig-0007}

3.8. Knockout of PCBP2 inhibited the progression of glioma in vivo {#jcp29104-sec-0230}
------------------------------------------------------------------

In this study, we also carried out the animal assay to verify the role of *PCBP2* in glioma progression. The results showed that tumor volume and weight in nude mice with glioma cells transfected by si‐*PCBP2* were significantly decreased, compared with si‐NC transfection group (Figure [8](#jcp29104-fig-0008){ref-type="fig"}a--c and *p* \< .05). Meanwhile, in vivo experiment, *FHL3* expression level was significantly upregulated in si‐*PCBP2* group (*p* \< .001 and Figure [8](#jcp29104-fig-0008){ref-type="fig"}d). Therefore, *PCBP2* could regulate the progression of glioma through targeting *FHL3*.

![Tumor volume was significantly decreased in nude mice with *PCBP2* knockdown (a and b); Tumor weight was obviously lower in si‐*PCBP2* group than that in si‐NC group (c); The expression level of *FHL3* was also upregulated in si‐*PCBP2* group (d). \**p* \< .05, \*\**p* \< .01, \*\*\**p* \< .001](JCP-235-3280-g008){#jcp29104-fig-0008}

4. DISCUSSION {#jcp29104-sec-0240}
=============

Glioma is a deadly malignancy, accounting for about 80% primary brain cancer (Omuro & DeAngelis, [2013](#jcp29104-bib-0019){ref-type="ref"}). To improve the outcome of glioma, it is crucial to explore the molecular mechanisms underlying the tumor progression of glioma. In the current study, we found that *PCBP2* silencing could inhibit glioma cell proliferation, migration and invasion, and promote cell apoptosis in vitro. *PCBP2* might participate in glioma progression through regulating *FHL3*/TGF‐β/Smad signaling pathway.

*PCBP2* is a RNA‐binding protein that can regulate RNA processing (Collier et al., [1998](#jcp29104-bib-0004){ref-type="ref"}; Wan et al., [2016](#jcp29104-bib-0025){ref-type="ref"}). Abnormal expression of *PCBP2* may lead to genetic alterations, thus leading to human diseases, like cancer. In our study, we found that the expression of *PCBP2* was significantly upregulated in glioma tissues and cells, compared with noncancerous tissues and normal cells. Furthermore, the elevated expression of *PCBP2* showed the positive association with tumor size and WHO stages of glioma. The conclusion was consistent with the previous studies. Luo et al. reported that the high expression of *PCBP2* was closely correlated with advanced tumor stage and poor prognosis of GBM patients and it might be a potential prognostic biomarker for GBM patients (Luo & Zhuang, [2017](#jcp29104-bib-0016){ref-type="ref"}). Increased expression of *PCBP2* may be a risk hallmark for glioma patients, predicting aggressive cancer progression.

Given their function in RNA processing process, *PCBP2* is involved in several cellular processes, such as cell proliferation, migration and invasion, as well as apoptosis. In the present study, in vitro experiments were performed to investigate the effects of *PCBP2* on biological behaviors of glioma cells. The results demonstrated that cell growth and motility (migration and invasion) were significantly inhibited, and cell apoptosis was enhanced in transfected glioma cells when *PCBP2* expression was decreased. Tang et al. ([2015](#jcp29104-bib-0022){ref-type="ref"}) indicated that the upregulation of *PCBP2* could remarkably promote the cell proliferation and growth of glioma in vitro. Lin et al. ([2016](#jcp29104-bib-0013){ref-type="ref"}) suggested that *PCBP2* could facilitate the migration and invasion of glioma cells. These previous studies all supported the conclusions obtained in our study. *PCBP2* may be an oncogene and therapeutic target in glioma.

In addition, we also investigated the molecular mechanisms of *PCBP2* in glioma progression. We found that the knockdown of *PCBP2* might lead to high expression of *FHL3* and low activity of TGF‐β/Smad signaling pathway in glioma cells. Besides, the expression of *FHL3* did not obviously influence the expression of *PCBP2*. Therefore, *FHL3* might be a downstream target gene of *PCBP2* in glioma. Moreover, the vivo mice experiment also verified the results in our study. A gene chip assay performed by Han et al. also indicated the link between *PCBP2* and *FHL3* in glioma progression (Han et al., [2013](#jcp29104-bib-0009){ref-type="ref"}). *PCBP2* may bind to 3′UTR of *FHL3* gene (Han, Xia, Yin, & Peng, [2014](#jcp29104-bib-0008){ref-type="ref"}). It has been reported to bind several target genes in diseases. *PCBP2* could regulate *CDK2* via direct 3′UTR binding in gastric cancer patients, which might be used as a potential biomarker for the therapy of gastric cancer (Chen et al., [2018](#jcp29104-bib-0002){ref-type="ref"}). Xin et al. also reported that *PCBP2* could promote the antiviral activity of *IFN‐α* against HCV by stabilizing the mRNA of *STAT1* and *STAT2* (Xin et al., [2011](#jcp29104-bib-0026){ref-type="ref"}). In addition, we found that the inhibition of *FHL3* expression might enhance TGF‐β/Smad signaling pathway activity in glioma cells which were transfected by si‐*PCBP2*. *FHL3* protein belongs to LIM‐only proteins family and can enhance phosphorylation and unclear accumulation of Smad proteins, thereby leading to the activation of tumor suppressor p21 and repression of oncogene c‐myc (Ding et al., [2009](#jcp29104-bib-0007){ref-type="ref"}). In the current study, we also found that knockdown of *FHL3* could reverse the tumor‐suppressive effects caused by *PCBP2* silencing expression in glioma. Therefore, *PCBP2* may activate TGF‐β/Smad signaling pathway through suppressing *FHL3*, thus contributing to the progression of glioma.

Certainly, several limitations in the current study should be stated. First, the sample size was relatively small that might reduce the statistical power of the current study. Second, the interaction between *PCBP2* and other genes, as well as relative signaling pathways which might play potential roles in cancer development were not investigated in our study. The progression of glioma is a complex process regulated by a netweb consisting with various genes, noncoding RNAs, pathways and proteins. To explain the development and progression of glioma, further research are required to explore the genetic regulatory netweb in glioma.

In conclusion, the upregulated expression of *PCBP2* can promote glioma progression including enhancing cell proliferation, migration and invasion, and inhibiting cell apoptosis. In glioma, *PCBP2* activates TGF‐β/Smad signaling pathway through targeting *FHL3* to participate in glioma progression.
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